Key facts
- This page summarizes John Patrick Shannon Jr.'s Form 4 filing for Xeris Biopharma Holdings, Inc. (XERS).
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Feb 2025, 19:40.
John Patrick Shannon Jr. - 31 Jan 2025 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)
- Reporting relationship
- Chief Executive Officer and Director, Director
- Issuer ticker
- XERS
- Reported as of
- 31 Jan 2025
- Net transaction value
- -$788,540
- SEC form
- 4
- Accepted by SEC
- 03 Feb 2025, 19:40:13 UTC
- Prior SEC filing
- 07 Jan 2025
- Next SEC filing
- 04 Aug 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Beth Hecht, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
John Patrick Shannon Jr. filed Form 4 for Xeris Biopharma Holdings, Inc. (XERS) on 03 Feb 2025.
Change
- Previous filing in this sequence was filed on 07 Jan 2025.
- Current net transaction value: -$788,540.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
XERS
transaction
Common Stock
Tax liability
- Transaction value
- $394,270
- Shares
- -110,750
- Change %
- -5.3%
- Price
- $3.56
- Shares after
- 1,997,868
- Date
- 31 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
XERS
transaction
Common Stock
Tax liability
- Transaction value
- $394,270
- Shares
- -110,750
- Change %
- -5.5%
- Price
- $3.56
- Shares after
- 1,887,118
- Date
- 31 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
XERS
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +800,000
- Change %
- +42%
- Price
- $0.000000
- Shares after
- 2,687,118
- Date
- 31 Jan 2025
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
XERS
transaction
Derivative
Stock Appreciation Right
Award
- Transaction value
- $0
- Shares
- +600,000
- Change %
- Price
- $0.000000
- Shares after
- 600,000
- Date
- 31 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 600,000
- Exercise price
- $3.56
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2025.
Footnote F2
These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years.
Footnote F3
This stock appreciation right granted under the Company's 2018 Stock Option and Incentive Plan will vest in full on the second anniversary of the January 31, 2025 grant date, subject to continued service with the company through the vesting date.
Footnote F4
Upon exercise, the stock appreciation right will be settled in cash.
SEC remarks
Chief Executive Officer and Director